soul trial oral semaglutide cardiovascular outcomes 2024 results nejm (NEJM 2025): led to a 14% Results of SOUL Trial with

Common gastrointestinal effects (Phase 2 NEJM) Retatrutide GI side effects at 12 mg in the Phase 2 NEJM trial Effect Nausea Rate at 12 mg Up to 25% Effect Diarrhea Rate at 12 mg Up to 23% Effect Vomiting Rate at 12 mg Up to 26% Effect Constipation Rate at 12 mg Up to 16% GI symptoms were most common during dose escalation and were usually mild to moderate

Corrales and colleagues [155] showed that osmoprotectants such as L-carnitine reduce activation of (mitogen-activated protein) MAP kinases, the phosphorylation of which leads to an increased expression of cytokines, chemokines and matrix metalloproteases [155]

A pill version could be much more appealing for patients who cant stand needles or just find a daily pill more convenient

p = 0.0001)